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Abstract 15 
The Friedländer condensation reaction between 2-aminonicotinealdehyde and 16 
acetophenone derivatives in presence of potassium hydroxide yielded 2-substituted-1,8-17 
napthyridine derivatives viz. 2-(1,8-napthyridin-2-yl)phenol (PHNp), 2-(1,8-napthyridin-2-18 
yl)aniline (AnNp) and 2-(pyridine-4-yl)-1,8-napthyridine (PyNp). Treatment of the chloro-19 
bridged dimers [(arene)MCl2]2 [arene = p-cymene, Cp*; M = Ru, Rh and Ir] with two 20 
equivalents of napthyridine ligands (PHNp, AnNp and PyNp) allowed the formation of 21 
mononuclear napthyridine complexes having formula [(arene)M(PHNp)Cl2] (1-3), 22 
[(arene)M(AnNp)Cl]PF6 (4-6) and [(arene)M(PyNp)Cl2] (7-9). These napthyridine compounds 23 
were isolated as neutral and cationic complexes which were further characterized by analytical 24 
and spectroscopic techniques. The molecular structures of some of the respective napthyridine 25 
complexes were established by carrying out the single crystal X-ray analysis. Single crystal X-26 
ray studies revealed the coordination of the napthyridine ligands to the metal center wherein 27 
AnNp ligand coordinated metal in a bidentate chelating NNʹ manner and PHNp and PyNp ligand 28 
coordinated metal in a monodentate fashion. In case of PHNp complexes the coordination occurs 29 
through napthyridine nitrogen N(1) whereas in case of PyNp complexes the coordination takes 30 
place through pyridine nitrogen N(1). These napthyridine complexes possessed cytotoxicity 31 
against HCT-116 (human colorectal cancer) and MIA-PaCa-2 (pancreatic carcinoma) cancer cell 32 
lines as compared to non-cancer cell line ARPE-19. 33 
Keywords: Ruthenium, rhodium, iridium, napthyridine’s, cytotoxicity  34 
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Introduction 35 
Arene ruthenium complexes are a well-known class of organometallic compounds 36 
generally referred to as half-sandwich complexes having potential applications in many arenas 37 
[1]. These organometallic compounds have been found to possess clinical as well as industrial 38 
applications [2]. Ruthenium complexes have also displayed remarkable activity in medicinal 39 
chemistry and these complexes have the potential to act as metal based anti-cancer drugs [3, 4]. 40 
Two such complexes in particular namely [Ru(η6-arene)Cl(en)]+ (en = ethylenediamine) and 41 
[Ru(cymene)Cl2(PTA)], known as RAPTA-C (PTA = 1,3,5-triaza-7-phosphaadamantane), have 42 
been found to possess excellent cytotoxic and anti-cancer activity both in vitro and in vivo 43 
including activity against cisplatin resistant cancer cells [5, 6]. Analogous to arene ruthenium 44 
complexes, Cp* rhodium and Cp* iridium complexes are also being studied as an alternative to 45 
platinum based drugs because of the inert facial co-ligand Cp* which is expected to offer several 46 
advantages such as water solubility and lability [7]. These complexes also serve as catalysts for 47 
various organic transformations such as hydrogenation and C-H activation [8, 9]. 48 
1,8-napthyridines represents an important class of ligands containing two fused pyridine 49 
rings and whose structure is closely related to bipyridines and phenanthrolines. These ligands 50 
possess several donor sites thus allowing them to act as monodentate, bidentate chelating and 51 
bridging coordinating ligand [10]. Substitution of an appropriate donor groups such as pyridyl, 52 
thiazolyl, furyl and pyrrole at the 2-position of 1,8-napthyridine provides a ligand, which can 53 
coordinate metal with the substituted ring in addition to the napthyridine ring [11]. The 54 
napthyridine ligands acts as a bridge to communicate between the two metal centers to come 55 
close to each other and which is expected to alter the bonding magnetic or energy transfer 56 
interactions. In cases where the donor groups attached at the 2-position of the napthyridine ring 57 
were substituted phenyl (F and OMe) and N-methyl pyrrole groups, interesting coordinating 58 
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chemistry has been observed for diruthenium complexes [12]. Despite having a rich diversified 59 
chemistry of napthyridine metal complexes, it is noteworthy that only a few half-sandwich 60 
platinum group metal napthyridine complexes have been reported to date [10, 13]. Based on the 61 
reactivity and different bonding modes of napthyridine ligands we anticipated that what would 62 
be the outcome if we substitute donor group such as phenol, aniline and pyridine at the 2-63 
position of the napthyridine ring. We assumed that the formed ligand would display distinctly 64 
unusual bonding modes and we have therefore explored this possibility in our present work. 65 
Ligands used in the present study are 2-(1,8-napthyridin-2-yl)phenol (PHNp), 2-(1,8-66 
napthyridin-2-yl)aniline (AnNp) and 2-(pyridine-4-yl)-1,8-napthyridine (PyNp). To the best of 67 
our knowledge the coordination chemistry of these ligands has not been explored previously. 68 
Herein, we report the synthesis and anti-cancer studies of ruthenium, rhodium and 69 
iridium half-sandwich complexes bearing phenol, aniline and 4-pyridyl groups substituted at 2-70 
position of 1,8-napthyridine moiety. 71 
Experimental 72 
Physical methods and materials 73 
The reagents used were of commercial quality and used without further purification. 74 
Metal chloride’s RuCl3.nH2O, RhCl3.nH2O and IrCl3.nH2O were purchased from Arora Matthey 75 
Limited. α-phellandrene, pentamethylcyclopentadiene and 2´-hydroxyacetophenone were 76 
purchased from Sigma-Aldrich. 2-aminonicotinaldehyde and 4-acetyl pyridine were obtained 77 
from Alfa Aesar and 2´-aminoacetophenone was obtained from Spectrochem. The solvents were 78 
dried and distilled prior to use according to standard procedures [14]. Precursor metal complexes 79 
[(p-cymene)RuCl2]2 and [Cp*MCl2]2 (M = Rh/Ir) were prepared according to the published 80 
procedures [15, 16]. 1H and 13C NMR spectra were recorded on a Bruker Advance II 400 MHz 81 
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spectrometer using CDCl3 and DMSO-d6 as solvents; chemical shifts were referenced to TMS. 82 
Infrared spectra (KBr pellets; 400-4000 cm-1) were recorded on a Perkin-Elmer 983 83 
spectrophotometer. Mass spectra were obtained from Waters ZQ 4000 mass spectrometer by ESI 84 
method using acetonitrile as solvent. Elemental analyses of the complexes were carried out on a 85 
Perkin-Elmer 2400 CHN/S analyzer. 86 
Structure determination by X-ray crystallography 87 
Solvent diffusion method was used for growing single crystals of compounds by layering 88 
solutions of the compounds in dichloromethane or chloroform with a fourfold excess of hexane 89 
and allowing them to stand undisturbed for one week. Suitable single crystal of compounds were 90 
chosen and glued onto the tip of glass fiber which was centered in the X-ray beam. The data for 91 
the complexes was collected on an Oxford Diffraction Xcalibur Eos Gemini diffractometer using 92 
graphite monochromated Mo-Kα radiation (λ = 0.71073 Å). The strategy for the data collection 93 
was evaluated using the CrysAlisPro CCD software. Crystal data were collected by standard 94 
‘‘phi–omega scan’’ techniques and were scaled and reduced using CrysAlisPro RED software. 95 
The structures were solved by direct methods using SHELXS-97 and refined by full-matrix least 96 
squares with SHELXL-97 refining on F2 [17, 18]. The positions of all the atoms were obtained 97 
by direct methods. Metal atoms in the complex were located from the E-maps and all non-98 
hydrogen atoms were refined anisotropically by full-matrix least-squares. Hydrogen atoms were 99 
placed in geometrically idealized positions and constrained to ride on their parent atoms with C--100 
-H distances in the range 0.95-1.00 Angstrom. Isotropic thermal parameters Ueq were fixed such 101 
that they were 1.2Ueq of their parent atom Ueq for CH's and 1.5Ueq of their parent atom Ueq in 102 
case of methyl groups. Crystallographic and structure refinement parameters for the complexes 103 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 7
are summarized in Table 1 and selected bond lengths and bond angles are presented in Table 2. 104 
Figures 1-5 were drawn with ORTEP3 program [19]. 105 
The crystal structure of complex (4) contains disordered DCM molecule. Crystal 106 
structure of complexes (8 and 9) contains CHCl3 molecule in their solved structure. 107 
Cell line testing 108 
The biological importance of the naphthyridines prompted us to study the cytotoxic 109 
activity of the synthesized napthyridine ligands and complexes. The cytotoxicity was tested 110 
against the HCT-116 colorectal carcinoma and MIA-PaCa-2 pancreatic carcinoma cell lines with 111 
the IC50 result shown in Table 3. Both cell lines were originally purchased from the American 112 
Type Culture Collection (ATCC) and all other reagents were purchased from Sigma Aldrich Co. 113 
Ltd (Dorset, UK) unless otherwise stated. The ARPE-19 cell line which is a non-cancer, human 114 
epithelial cell line derived from the retina and this was also obtained from ATCC. Cytotoxicity 115 
of ligands and compounds were evaluated using the standard MTT 3-(4,5-Dimethylthiazol-2-yl)-116 
2,5-diphenyltetrazolium bromide cellular viability assay as follows. Cells were inoculated into 117 
96 well plates at 1.5 x 103 cells per well and incubated at 37 °C in an atmosphere of 5% CO2 118 
prior to drug exposure. The napthyridine ligands (Scheme 1) and complexes (1-9) (Scheme 2) 119 
were all dissolved in DMSO at a concentration of 25 mM and diluted further with medium to 120 
obtain drug solutions ranging from 0.5 to 150 µM. Cisplatin was dissolved in phosphate buffered 121 
saline at a stock concentration of 25 mM. The final DMSO concentration was 0.2% (v/v), which 122 
is nontoxic to cells. Cells were exposed to drug for 96 hours and cell survival was determined 123 
using the MTT assay [20, 21]. Following drug exposure, 20 µL of MTT (0.5 mg/ml) in 124 
phosphate buffered saline was added to each well and it was further incubated at 37 °C for 4 125 
hours in an atmosphere of 5% CO2. The solution was then removed and the formed formazan 126 
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crystals was dissolved in 150 µM DMSO and the absorbance of the solution was recorded at 550 127 
nm using an ELISA spectrophotometer. Percentage cell survival was calculated by dividing the 128 
true absorbance of treated cell by the true absorbance for controls (exposed to 0.2% DMSO). The 129 
IC50 values were determined from plots of % survival against drug concentration. Each 130 
experiment was repeated three times and a mean value obtained and stated as IC50 (µM) ± SD. 131 
Synthesis of 2-substituted-1,8-napthyridine ligands 132 
The ligands 2-(1,8-napthyridin-2-yl)phenol (PHNp), 2-(1,8-napthyridin-2-yl)aniline 133 
(AnNp) and 2-(pyridine-4-yl)-1,8-napthyridine (PyNp) were synthesized according to 134 
Friedländer condensation (Scheme 1) [22]. Herein a detailed procedure is provided only for 2-135 
(1,8-napthyridin-2-yl)phenol (L1). A stirred solution of 2´-hydroxy acetophenone (408 mg, 3 136 
mmol), 2-aminonicotinealdehyde (366 mg, 3 mmol) and KOH (336 mg, 6 mmol) in 50% 137 
aqueous methanol (10 mL) was heated to 60 °C overnight. The reaction mixture was quenched 138 
by the addition of water (20 mL) and the resulting precipitate was isolated by filtration. The 139 
crude product was washed with water, dried in vacuum and collected. 140 
2-(1,8-napthyridin-2-yl)phenol (PHNp) 141 
Color: Orange crystals; Yield: 82 %; IR (KBr, cm-1): 3521(b), 3224(m), 2961(m), 2870(w), 142 
1644(s), 1469(m), 1358(m); 1H NMR (400 MHz, CDCl3): δ = 14.7 (s, 1H, OH), 8.26 (d, 1H, J = 143 
12 Hz), 8.15 (d, 1H, J = 8 Hz), 8.08 (d, 1H, J = 8 Hz), 7.90 (d, 1H, J = 8 Hz), 7.43-7.46 (m, 1H), 144 
7.31-7.34 (m, 1H), 7.24 (d, 1H, J = 8 Hz), 7.06 (d, 1H, J = 8 Hz), 6.88-6.92 (m, 1H); Anal. Calc 145 
for C14H10N2O (222.24); C, 75.66; H, 4.54; N, 12.60. Found: C, 75.76; H, 4.67; N, 12.73 %. 146 
2-(1,8-napthyridin-2-yl)aniline (AnNp) 147 
Color: Yellow crystals; Yield: 86 %; IR (KBr, cm-1): 3402(s), 3293(m), 3058(w), 2922(w), 148 
1611(s), 1566(m), 1541(m), 1499(m), 1257(m); 1H NMR (400 MHz, DMSO-d6): δ = 8.84 (dd, 149 
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1H, J = 4 and 4 Hz), 8.28 (d, 1H, J = 8 Hz), 8.25 (dd, 1H, J = 4 and 4 Hz), 8.00 (d, 1H, J = 8 150 
Hz), 7.70 (d, 1H, J = 8Hz), 7.38-7.41 (m, 1H), 7.34 (s, 2H, NH2), 6.98 (t, 1H, J = 8 Hz), 6.65 (d, 151 
1H, J = 8 Hz), 6.46 (t, 1H, J = 8 Hz); Anal. Calc for C14H11N3 (221.25); C, 76.00; H, 5.01; N, 152 
18.99. Found: C, 76.09; H, 5.12; N, 19.08 %. 153 
2-(pyridine-4-yl)-1,8-napthyridine (PyNp) 154 
Color: White powder; Yield: 65 %; IR (KBr, cm-1): 3021(m), 2927(m), 2811(m), 1634(m), 155 
1587(m), 1494(m), 1340(s); 1H NMR (400 MHz, CDCl3): δ = 9.21 (dd, 1H, J = 4 and 4 Hz), 156 
8.82 (d, 2H, J = 8 Hz), 8.38 (d, 1H, J = 8 Hz), 8.28 (dd, 1H, J = 8 and 8 Hz), 8.20 (d, 2H, J = 8 157 
Hz), 8.07 (d, 1H, J = 8 Hz), 7.54-7.57 (m, 1H); Anal. Calc for C13H19N3 (207.23); C, 75.35; H, 158 
4.38; N, 20.28. Found: C, 75.47; H, 4.46; N, 20.41 %. 159 
General procedure for preparation of neutral napthyridine complexes (1-3) 160 
A mixture of metal precursor [(arene)MCl2]2 (arene = p-cymene, Cp*; M = Ru, Rh and 161 
Ir) (0.1 mmol) and ligand 2-(1,8-napthyridin-2-yl)phenol (PHNp) (0.2 mmol) were dissolved in 162 
dichloromethane and the reaction mixture was stirred overnight at room temperature. This 163 
solution was then filtered over celite and the solvent was evaporated under reduced pressure to 164 
afford yellow solid which was washed with diethyl ether (2 x 10 mL) and air dried (Scheme 2). 165 
[(p-cymene)Ru(PHNp)Cl2] (1) 166 
Yield: 69 mg (75%); IR (KBr, cm-1): 3411(b), 3056(m), 1611(m), 1585(m), 1548(m), 1508(m), 167 
1473(m), 1249(m), 1155(s); 1H NMR (400 MHz, DMSO-d6): δ = 14.92 (s, 1H, OH), 8.89 (d, 1H, 168 
J = 4 Hz), 8.48 (d, 1H, J = 8 Hz), 8.31 (t, 2H, J = 8 Hz), 8.07 (d, 1H, J = 8 Hz), 7.47-7.50 (m, 169 
1H), 7.22 (t, 1H, J = 8 Hz), 6.77-6.82 (m, 2H), 5.61 (d, 2H, J = 4 Hz, CH(p-cym)), 5.57 (d, 2H, J = 170 
8 Hz, CH(p-cym)), 2.61 (sept, 1H, CH(p-cym)), 1.86 (s, 3H, CH(p-cym)), 0.98 (d, 6H, J = 8 Hz, CH(p-171 
cym)); 13C NMR (100 MHz, DMSO-d6): δ (ppm) = 160.60, 160.29, 155.19, 149.35, 138.65, 172 
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135.10, 133.83, 128.16, 121.69, 121.11, 119.92, 118.16, (C-PHNp), 105.51, 103.91, 87.71, 173 
84.21, 30.31, 23.81, 17.41 (C-p-cym); ESI-MS (m/z) [Found (Calcd)]: [456.96 (457.08)] [M-Cl-174 
HCl]+; Anal. Calc for C24H24Cl2N2ORu (528.43); C, 54.55; H, 4.58; N, 5.30. Found: C, 54.64; H, 175 
4.67; N, 5.39 %. 176 
[Cp*Rh(PHNp)Cl2] (2) 177 
Yield: 82 mg (77%); IR (KBr, cm-1): 3434(b), 2137(m), 1608(m), 1503(m), 1475(m), 1384(m), 178 
1137(m); 1H NMR (400 MHz, DMSO-d6): δ = 15.12 (s, 1H, OH), 9.10 (d, 1H, J = 4 Hz), 8.68 179 
(d, 1H, J = 8 Hz), 8.51 (d, 2H, J = 8 Hz), 8.26 (d, 2H, J = 4 Hz), 7.67-7.70 (m, 1H), 7.42 (t, 1H, J 180 
= 8 Hz), 6.97-7.02 (m, 1H), 1.60 (s, 15H, CH(Cp*)); 13C NMR (100 MHz, DMSO-d6): δ = 160.61, 181 
160.29, 154.49, 152.35, 139.65, 137.30, 132.83, 128.16, 122.69, 121.11, 118.92, 118.83, 118.18 182 
(C-PHNp), 98.68 (Cp*ipso), 8.51 (Cp*Me); ESI-MS (m/z) [Found (Calcd)]: [459.02 (459.09)] [M-183 
Cl-HCl]+; Anal. Calc for C24H25Cl2N2ORh (531.27); C, 54.26; H, 4.74; N, 5.27. Found: C, 54.37; 184 
H, 4.87; N, 5.41 %. 185 
[Cp*Ir(PHNp)Cl2] (3) 186 
Yield: 98 mg (78%); IR (KBr, cm-1): 3401(b), 2918(w), 2150(m), 1632(m), 1608(m), 1503(m), 187 
1475(m), 1137(m); 1H NMR (400 MHz, DMSO-d6): δ = 15.12 (s, 1H, OH), 9.10 (dd, 1H, J = 4 188 
and 4 Hz), 8.68 (d, 1H, J = 8 Hz), 8.51 (t, 2H, J = 8 Hz), 8.27 (d, 1H, J = 8 Hz), 7.67-7.70 (m, 189 
1H), 7.42 (t, 1H, J = 8 Hz), 6.98-7.02 (m, 2H), 1.61 (s, 15H, CH(Cp*)); 13C NMR (100 MHz, 190 
DMSO-d6): δ = 160.62, 160.30, 154.49, 152.36, 139.65, 137.30, 132.83, 128.17, 122.69, 121.11, 191 
118.92, 118.26, 118.18 (C-PHNp), 92.01 (Cp*ipso), 8.17 (Cp*Me); ESI-MS (m/z) [Found 192 
(Calcd)]: [549.10 (549.15)] [M-Cl-HCl]+; Anal. Calc for C24H25Cl2N2OIr (620.59); C, 46.45; H, 193 
4.06; N, 4.51. Found: C, 46.58; H, 4.14; N, 4.62 %. 194 
 195 
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General procedure for preparation of cationic napthyridine metal complexes (4-6) 196 
A mixture of metal precursor [(arene)MCl2]2 (arene = p-cymene, Cp*; M = Ru, Rh and 197 
Ir) (0.1 mmol) and 2-(1,8-napthyridin-2-yl)aniline (AnNp) were dissolved in dry methanol (5 198 
mL) and stirred at room temperature for 1 hour. Then 4 equivalents of NH4PF6 dissolved in dry 199 
methanol (2 mL) was added dropwise to the reaction mixture and stirring continued for further 5-200 
6 hours whereupon a yellow solid precipitated out from the reaction mixture. The precipitate was 201 
filtered, washed with cold methanol (2 x 5 ml) and diethyl ether (2 x 10 ml) and air dried 202 
(Scheme 2). 203 
[(p-cymene)Ru(AnNp)Cl]PF6 (4) 204 
Yield: 101 mg (79%); IR (KBr, cm-1): 3314(m), 3125(m), 1604(m), 1494(w), 1462(w), 1111(m), 205 
842(s); 1H NMR (400 MHz, DMSO-d6): δ = 9.86 (d, 1H, J = 12 Hz), 8.97 (d, 1H, J = 4 Hz), 8.70 206 
(d, 1H, J = 8 Hz), 8.27 (d, 1H, J = 8 Hz), 8.00 (d, 1H, J = 4 Hz), 7.86 (t, 1H, J = 8 Hz), 7.51-7.57 207 
(m, 2H), 7.31 (t, 2H, J = 8 Hz), 5.99 (dd, 2H, J = 4 and 4 Hz, CH(p-cym)), 5.59 (d, 1H, J = 8.0 Hz, 208 
CH(p-cym)), 5.54 (d, 1H, J = 8 Hz, CH(p-cym)), 2.19 (sept, 1H, CH(p-cym)), 1.98 (s, 3H, CH(p-cym)), 209 
0.98 (d, 3H, J = 8 Hz, CH(p-cym)), 0.89 (d, 3H, J = 4 Hz, CH(p-cym)); 13C NMR (100 MHz, DMSO-210 
d6): δ = 161.78, 158.61, 155.19, 148.13, 138.12, 137.32, 134.18, 129.14, 123.41, 120.05, 119.18, 211 
117.16, (C-AnNp), 106.14, 103.41, 89.51, 87.11, 85.22, 30.71, 23.81, 20.21, 16.41 (C-p-cym); 212 
ESI-MS (m/z) [Found (Calcd)]: [492.06 (492.07)] [M-PF6]+, ESI-MS (m/z) [Found (Calcd)]: 213 
[456.0 (456.10)] [M-PF6-HCl]+; Anal. Calc for C24H25ClN3F6PRu (636.96); C, 45.25; H, 3.96; N, 214 
6.60. Found: C, 45.38; H, 4.07; N, 6.71 %. 215 
[Cp*Rh(AnNp)Cl]PF6 (5) 216 
Yield: 93 mg (72%); IR (KBr, cm-1): 3269(w), 2923(w), 1606(m), 1491(w), 1462(w), 843(s); 1H 217 
NMR (400 MHz, DMSO-d6): δ = 9.23 (d, 1H, J = 4 Hz), 8.81 (d, 1H, J = 8 Hz), 8.63 (d, 1H, J = 218 
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8 Hz), 8.25 (d, 1H, J = 8 Hz), 7.93 (d, 1H, J = 8 Hz), 7.77-7.80 (m, 1H), 7.65 (t, 1H, J = 4 Hz), 219 
7.47-7.54 (m, 2H), 7.40 (t, 1H, J = 8 Hz), 6.71 (d, 1H, J = 4 Hz), 1.34 (s, 15H, CH(Cp*)); 13C 220 
NMR (100 MHz, DMSO-d6): δ = 161.34, 157.13, 153.61, 142.01, 140.24, 139.21, 135.47, 221 
133.45, 126.14, 124.16, 123.12, 120.33, 118.23 (C-AnNp), 89.38 (Cp*ipso), 8.13 (Cp*Me); ESI-222 
MS (m/z) [Found (Calcd)]: [494.05 (494.08)] [M-PF6]+, ESI-MS (m/z) [Found (Calcd)]: [458.06 223 
(458.11)] [M-PF6-HCl]+; Anal. Calc for C24H26ClN3F6PRh (639.80); C, 45.05; H, 4.10; N, 6.57. 224 
Found: C, 45.15; H, 4.21; N, 6.63 %. 225 
[Cp*Ir(AnNp)Cl]PF6 (6) 226 
Yield: 110 mg (75%); IR (KBr, cm-1): 3316(w), 3254(w), 3065(w), 2923(w), 1606(m), 1462(w), 227 
1154(w), 842(s); 1H NMR (400 MHz, CDCl3): δ = 9.34 (d, 1H, J = 12 Hz), 8.85 (d, 1H, J = 8 228 
Hz), 8.49 (d, 1H, J = 8 Hz), 8.18 (d, 1H, J = 4 Hz), 8.10 (d, 1H, J = 8 Hz), 8.01 (d, 1H, J = 8 Hz), 229 
7.80 (d, 1H, J = 8 Hz), 7.57 (t, 1H, J = 4 Hz), 7.34 (t, 1H, J = 8 Hz), 7.23 (d, 1H, J = 4 Hz), 6.69 230 
(d, 1H, J = 12 Hz), 1.39 (s, 15H, CH(Cp*)); 13C NMR (100 MHz, DMSO-d6): δ = 160.04, 153.63, 231 
152.89, 142.01, 141.33, 137.57, 131.89, 131.45, 125.84, 123.78, 123.62, 123.36, 119.22 (C-232 
AnNp), 86.38 (Cp*ipso), 8.07 (Cp*Me); ESI-MS (m/z) [Found (Calcd)]: [584.07 (584.14)] [M-233 
PF6]+, ESI-MS (m/z) [Found (Calcd)]: [548.15 (548.16)] [M-PF6-HCl]+; Anal. Calc for 234 
C24H26ClN3F6PIr (729.11); C, 39.54; H, 3.59; N, 5.76. Found: C, 39.66; H, 3.68; N, 5.82 %. 235 
General procedure for preparation of neutral napthyridine metal complexes (7-9) 236 
A mixture of metal precursor [(arene)MCl2]2 (arene = p-cymene, Cp*; M = Ru, Rh and 237 
Ir) (0.1 mmol) and ligand 2-(pyridine-4-yl)-1,8-napthyridine (PyNp) (0.2 mmol) were dissolved 238 
in dry methanol (5 mL) and stirred at room temperature for 6 hours. A yellow compound 239 
precipitated out from the reaction mixture. The precipitate was collected washed with cold 240 
methanol (2 x 5 mL) and diethyl ether (3 x 10 mL) and air dried (Scheme 2). 241 
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[(p-cymene)Ru(PyNp)Cl2] (7) 242 
Yield: 72 mg (70%); IR (KBr, cm-1): 2965(m), 2870(m), 1637(m), 1615(m), 1384(w), 1124(m); 243 
1H NMR (400 MHz, CDCl3): δ = 9.14 (s, 3H), 8.35 (d, 1H, J = 8 Hz), 8.24 (d, 1H, J = 8 Hz), 244 
8.08 (d, 2H, J = 8 Hz), 7.95 (d, 1H, J = 8 Hz), 7.53-7.57 (m, 1H), 5.45 (d, 2H, J = 4 Hz, CH(p-245 
cym)), 5.22 (d, 2H, J = 4 Hz CH(p-cym)), 2.94 (sept, 1H, CH(p-cym)), 2.06 (s, 3H, CH(p-cym)), 1.28 (d, 246 
6H, J = 8 Hz, CH(p-cym)); 13C NMR (100 MHz, CDCl3): δ = 155.78, 154.16, 153.19, 148.23, 247 
139.12, 136.21, 135.11, 130.14, 128.06, 123.05, 119.18, 118.16, (C-PyNp), 106.18, 103.41, 248 
90.13, 88.41, 30.20, 21.84, 17.80 (C-p-cym); ESI-MS (m/z) [Found (Calcd)]: [478.21 (478.06)] 249 
[M-Cl]+, ESI-MS (m/z) [Found (Calcd)]: [442.15 (443.09)] [M-2Cl]+; Anal. Calc for 250 
C23H23Cl2N3Ru (513.42); C, 53.80; H, 4.52; N, 8.18. Found: C, 53.93; H, 4.63; N, 8.29 %. 251 
[Cp*Rh(PyNp)Cl2] (8) 252 
Yield: 92 mg (89%); IR (KBr, cm-1): 2985(m), 2860(m), 1635(m), 1609(m), 1378(w), 1127(m); 253 
1H NMR (400 MHz, CDCl3): δ = 9.19 (s, 1H), 9.15 (d, 2H, J = 4 Hz), 8.45 (d, 1H, J = 8 Hz), 254 
8.31 (dd, 1H, J = 4 and 4 Hz), 8.21 (d, 1H, J = 8 Hz), 8.04 (d, 2H, J = 8 Hz), 7.56-7.59 (m, 1H), 255 
1.63 (s, 15H, CH(Cp*)); 13C NMR (100 MHz, CDCl3): δ = 156.31, 155.42, 154.34, 153.18, 256 
148.33, 139.24, 137.14, 123.43, 123.35, 123.07, 118.14 (C-PyNp), 87.12 (Cp*ipso), 8.63 (Cp*Me); 257 
ESI-MS (m/z) [Found (Calcd)]: [480.07 (480.15)] [M-Cl]+, ESI-MS (m/z) [Found (Calcd)]: 258 
[444.16 (445.10)] [M-2Cl]+; Anal. Calc for C23H24Cl2N3Rh (516.26); C, 53.51; H, 4.69; N, 8.14. 259 
Found: C, 53.62; H, 4.76; N, 8.23 %. 260 
[Cp*Ir(PyNp)Cl2] (9) 261 
Yield: 86 mg (71%); IR (KBr, cm-1): 2991(m), 2875(m), 1631(m), 1611(m), 1374(w), 1125(m); 262 
1H NMR (400 MHz, CDCl3): δ = 9.20 (s, 1H), 9.13 (d, 2H, J = 8 Hz), 8.45 (d, 1H, J = 8 Hz), 263 
8.31 (dd, 1H, J = 4 and 4 Hz), 8.19 (d, 2H, J = 4 Hz), 8.06 (d, 1H, J = 8 Hz), 7.57-7.60 (m, 1H), 264 
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1.58 (s, 15H, CH(Cp*)); 13C NMR (100 MHz, CDCl3): δ = 155.70, 155.59, 154.74, 153.88, 265 
147.30, 139.32, 137.14, 123.56, 123.10, 123.02, 119.83 (C-PyNp), 86.0 (Cp*ipso), 8.58 (Cp*Me); 266 
ESI-MS (m/z) [Found (Calcd)]: [570.21 (570.12)] [M-Cl]+, ESI-MS (m/z) [Found (Calcd)]: 267 
[534.23 (535.15)] [M-2Cl]+; Anal. Calc for C23H24Cl2N3Ir (605.07); C, 45.62; H, 3.99; N, 6.94. 268 
Found: C, 45.79; H, 4.08; N, 7.05 %. 269 
Results and discussion 270 
Synthesis of napthyridine ligands and metal complexes 271 
The napthyridine ligands were synthesized according to Friedländer condensation 272 
reaction and the napthyridine metal complexes (1-9) were synthesized by the reaction of metal 273 
precursors with respective napthyridine ligands. At first the reaction of PHNp with metal 274 
precursor was carried out using triethylamine as base with an aim of deprotonating phenolic 275 
hydrogen which would result in formation of NO chelated complex but no deprotonation 276 
occurred as evidenced from the 1H NMR spectra of the complexes which showed the presence of 277 
phenolic proton. So the reaction was carried out without using triethylamine and which resulted 278 
in formation of the same compounds. X-ray studies revealed that the PHNp ligand coordinated 279 
metal in a monodentate manner through napthyridine nitrogen. Reaction of AnNp with precursor 280 
afforded mononuclear bidentate chelated complexes. Surprisingly substituting 4-pyridyl group at 281 
the 2-position of 1,8-napthyridine in PyNp yielded complexes where PyNp is coordinated to 282 
metal through pyridine nitrogen rather than napthyridine nitrogen as in case of PHNp complexes. 283 
The three-napthyridine ligands used in this work exhibited interesting coordination modes. 284 
Complexes of PHNp and PyNp ligands were isolated as neutral complexes whereas with AnNp 285 
ligand, complexes were isolated as ionic salts with PF6 counter ion. The napthyridine ligands and 286 
metal complexes were obtained in good yields. These complexes are soluble in organic solvents 287 
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such as chloroform, dichloromethane, acetonitrile and DMSO but insoluble in diethyl ether and 288 
hexane. The napthyridine ligands and the napthyridine metal complexes were characterized 289 
spectroscopically and the molecular structures of some of the complexes were established by 290 
single crystal X-ray analysis. 291 
Spectroscopic characterization of napthyridine ligands 292 
The infrared spectra of PHNp and AnNp ligands exhibited stretching frequencies for OH 293 
at 3521 cm-1 and for the NH2 group at 3402 and 3293 cm-1. The C=N and C=C stretching 294 
frequencies of the napthyridine ligands were observed in the range of 1450-1650 cm-1. The 295 
proton NMR spectra of the napthyridine ligands displayed signals in the range of 6.46-9.21 ppm 296 
for the protons of the napthyridine moiety and substituted rings. In addition to these resonances 297 
the PHNp ligand displayed a singlet at 14.7 ppm for the phenolic proton and the AnNp ligand 298 
exhibited a broad singlet for the NH2 proton at 7.34 ppm respectively. The respective 1H NMR 299 
spectra of the napthyridine ligands are presented in the SI. 300 
Spectroscopic characterization of napthyridine metal complexes  301 
IR studies of metal complexes 302 
The IR spectra of the metal complexes suggest the coordination of the napthyridine 303 
ligands to the metal atom. The presence of a broad band for complexes (1-3) in the lower 304 
frequency region around 3401-3434 cm-1 for the phenolic OH group suggests that the phenolic 305 
group is not involved in coordination to the metal center. This was further supported by NMR 306 
and single crystal analysis. Complexes (4-6) displayed characteristic stretching frequencies for 307 
NH2 group at lower frequency region around 3125-3326 cm-1 as compared to the free ligand at 308 
3402 and 3293 cm-1. This shift to lower frequency suggests the coordination of the NH2 group. 309 
Further the C=N stretching frequencies of the complexes decreases slightly and was observed in 310 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 16 
the range of 1603-1615 cm-1 as compared to the free ligand which suggest the coordination of the 311 
napthyridine and pyridine nitrogen’s. In addition to these bands a sharp band for the cationic 312 
complexes (4-6) was observed around 842-843 cm-1 attributed to the P-F stretching frequency of 313 
the counter ion [23]. 314 
1H NMR studies of metal complexes 315 
The 1H NMR spectra of the metal complexes further support the formation of the 316 
complexes. The resulting spectra are depicted in the supplementary information and ensuing data 317 
are summarized in the experimental section. The metal complexes exhibited signals associated 318 
with the ligand protons and signals due to p-cymene and Cp* ring protons. The signals 319 
associated with the napthyridine and substituted ring protons were observed in the downfield 320 
region around 6.65-9.86 ppm. This shifting of the ligand resonances indicates the coordination of 321 
the napthyridine ligands to the metal atom. Also the appearance of the phenolic proton signals in 322 
complexes (1-3) around 14.9-15.1 ppm confirms that the phenolic OH group is not involved in 323 
coordination to the metal atom. Further confirmation of the binding of napthyridine ligands was 324 
confirmed by the appearance of the p-cymene and Cp* ring proton signals. The aromatic protons 325 
of the p-cymene ligand consisted of doublets around 5.22-5.99 ppm. The isopropyl group of the 326 
p-cymene ligand displayed doublet for complexes (1 and 7) whereas for complex (4) it showed 327 
two doublets around 0.89-1.28 ppm. The methyl and methine protons of the p-cymene ligand 328 
were observed as a singlet around 1.98-2.07 ppm and septet around 2.19-2.94 ppm. The methyl 329 
protons of the Cp* moiety was observed as a singlet around 1.34-1.61 ppm. 330 
13C NMR studies of metal complexes 331 
The 13C NMR spectra further justify the formation of the complexes. The 13C NMR 332 
spectra of the complexes displayed signals associated with the napthyridine carbons and the 333 
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appearance of the p-cymene moiety carbons, methyl carbon of Cp* and ring carbon of Cp* 334 
confirms the formation of these complexes. In the 13C NMR spectra of the complexes the carbon 335 
resonances associated with the napthyridine ligand were observed in the region around 118-161 336 
ppm. The aromatic carbon resonances of the p-cymene ligand were observed in the region 337 
around 84-106 ppm. The methine, isopropyl and methyl carbon resonances of the p-cymene 338 
moiety were observed in the region around 16-31 ppm. In addition to these carbon resonances 339 
the ring carbons of the Cp* ligand displayed signal around 86.0-98.6 ppm and the signal for the 340 
methyl protons of the Cp* moiety was observed around 8.07-8.63 ppm. Overall results from 341 
NMR spectral studies strongly support the formation of the metal complexes. 342 
Mass spectral studies of metal complexes 343 
The composition and formation of napthyridine metal complexes (1-9) have further been 344 
justified by ESI-mass spectral studies. The mass spectra of the complexes are presented in the 345 
supplementary information and the values are listed in the experimental section (2.5). The mass 346 
spectra of the complexes (1–3) displayed their molecular ion peaks at m/z: 456.96, m/z: 459.02 347 
and m/z: 549.10 corresponding to [M-Cl-HCl]+ ion. Complexes (4-6) displayed their molecular 348 
ion peaks at m/z: 492.06, m/z: 494.05 and m/z: 584.07 which corresponds to [M-PF6]+ ion peak. 349 
Also peaks were observed at m/z: 456.0, m/z: 458.06 and m/z: 548.15 which is due to [M-PF6-350 
HCl]+ ion. Similarly complexes (7-9) displayed peaks at m/z: 478.21, m/z: 480.15 and m/z: 351 
570.21 which is due to the loss of one chloride [M-Cl]+ ion and also it exhibited peaks at m/z: 352 
442.15, m/z: 444.16 and m/z: 534.23 which is due to the loss of both the chloride [M-2Cl]+ ion. 353 
Description of the crystal structures of complexes 354 
Apart from spectroscopic analysis, the molecular structures of some of the respective 355 
complexes were established by single crystal X-ray analysis. Our attempt to isolate the single 356 
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crystal for all the complexes was unsuccessful; however we obtained single crystals for the 357 
PHNp ligand and complexes 3, 4, 5, 8 and 9 respectively. By carrying out the single crystal 358 
analyses we were able to confirm the various coordination modes of the napthyridine ligand and 359 
the geometry of the complexes. The data and molecular structure of complexes 3 and 9 presented 360 
here is to only confirm the structure and composition of the molecule. The ORTEP plot of PHNp 361 
and the complexes along with atom numbering scheme are shown in (Figures 1-5) respectively. 362 
The summary of the crystal data including data collection and structure refinement parameters 363 
are summarized in Table 1 and geometrical parameters including bond lengths, bond angles and 364 
metal atom involving ring centroid values are listed in Table 2. The molecular structure of PHNp 365 
ligand is shown in (Figure 1). Complexes (1-3) and (7-9) have the neutral species with formula 366 
[(arene)M(PHNp)Cl2] and [(arene)M(PyNp)Cl2] [(arene) = p-cymene, M = Ru (1), (7); Cp*, M = 367 
Rh (2), (8) and Ir (3), (9)]. Complexes (4-6) have the cationic species with general formula 368 
[(arene)M(AnNp)Cl] [(arene) = p-cymene, M = Ru (4); Cp*, M = Rh (5) and Ir (6)] and counter 369 
anion PF6. These complexes adopts a familiar three legged piano-stool geometry around the 370 
metal center with coordination sites occupied by arene/Cp* ring (arene = p-cymene and Cp*) in 371 
a η6/η5 manner, nitrogen donor atoms from napthyridine ligand and terminal chloride. The 372 
geometry at the metal atom is pseudo-octahedral wherein the polycyclic arene ligand acts as seat 373 
and napthyridine ligand and terminal chloride form the legs. In complex (3) iridium metal is 374 
coordinated through Cp* ring, PHNp ligand in a monodentate fashion coordinating iridium 375 
through napthyridine nitrogen (N1) and two chlorides thus possessing a three-legged piano-stool 376 
structure (Figure 2). In complexes 4 and 5 the metal is coordinated through p-cymene and Cp* 377 
ring, AnNp ligand in a bidentate manner and one chloride. The AnNp ligand acts as a chelating 378 
ligand coordinating metal through aniline nitrogen N(1) and napthyridine nitrogen (N2) forming 379 
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a six membered metallacycle (Figure 3). The napthyridine nitrogen N(3) is not involved in 380 
coordination. Similarly in complex 8 the metal is coordinated through two chloride’s, Cp* 381 
moiety and PyNp ligand wherein it acted as a neutral monodentate ligand coordinating rhodium 382 
through pyridine nitrogen (N1) (Figure 4 and 5). The distance between the metal to centroid of 383 
the arene/Cp* ring are {1.775 (3), 1.799 (4), 1.803 (5) and 1.773 (8) and 1.778 (9) Å}. The Metal 384 
to nitrogen (M-N) bond distances in these complexes is found to be in the range of 2.11-2.17 Å 385 
which are in close agreement for reported complexes with napthyridine ligands (Table 2) [10, 386 
13]. It is to be noted that in complexes (4 and 5) the M-N bond distance {2.143(3) and 2.138(2), 387 
Å} from aniline N(1) is comparatively shorter than the napthyridine N(2) nitrogen-metal 388 
distances {2.164(3) and 2.179(3) Å}. The M-Cl bond lengths in these complexes shows no 389 
significant differences and was found to be in the range of 2.405-2.447 Å which are comparable 390 
with earlier reported complexes [24]. The bite angle values in in these napthyridine complexes 391 
were observed in the range of 80.0-91.3° which are consistent with the piano stool arrangement 392 
of various groups around the metal center (Table 2) [25, 26]. 393 
Further from the crystal packing diagram it was observed that complex (4) formed a 394 
dimeric unit via intermolecular van der Waal N-H·····Cl (2.647 Å) interaction between the 395 
terminal chloride and amino hydrogen (Figure 6). Also in complex (5) two different types of 396 
weak intermolecular van der Waal N-H·····Cl (2.548 Å) between chloride and amino group of 397 
AnNp and C-H·····Cl (2.815 Å) interactions between chloride and napthyridine hydrogen was 398 
observed (Figure 7). Interestingly the crystal packing in complex (8) formed a dimeric unit via 399 
intermolecular van der Waal C-H·····Cl (2.723 and 2.809 Å) interaction between the chloride ion 400 
and H-atom from napthyridine and pyridine of PyNp (Figure 8). These weak interactions play a 401 
significant role in the formation of supramolecular motifs with interesting features. 402 
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Chemosensitivity studies 403 
The response of HCT-116 and MIA-PaCa-2 cells to the napthyridine ligands and the 404 
respective metal complexes (1-9) are presented in Table 3. PHNp ligand was found to be 405 
moderately active against both HCT-116 and MIA-PaCa-2 cell lines with IC50 values of 406 
39.90±1.60 and 62.48±6.28 µM respectively. In contrast, both AnNp and PyNp were found to be 407 
inactive with IC50 value > 100 µM against both the cell lines. Upon complexation of napthyridine 408 
ligands complexes (1-3) of PHNp ligand displayed less activity whereas PyNp complexes did not 409 
display any cytotoxicity and iridium complex (6) with AnNp ligand possessed the highest 410 
activity against HCT-116 cells. Complexes (1-3) were found to be active against HCT-116 cell 411 
line with IC50 value in the range of 37.79±4.90 to 82.09±3.55 µM as compared to PHNp ligand 412 
whose IC50 value is 39.90±1.60 µM. Against the Mia-PaCa-2 cell line, complex (2) was the most 413 
active with an IC50 of 25.13±6.07 µM. Complexes (3) and (6) were moderately active against the 414 
MIA-PaCa-2 cell line with IC50 values of 52.13±12.28 and 82.09±2.55 µM. Differences between 415 
the response of HCT116 and Mia-PaCa-2 cells exist suggesting that these complexes are 416 
targeting inherent biochemical differences between these cells as opposed to having general 417 
cytotoxic properties. However, all the compounds were found to be less cytotoxic as compared to 418 
cisplatin whose IC50 value is 2.78 µM. In contrast to cisplatin however, none of the novel 419 
compounds tested exhibited a cytotoxic effect on the non-cancer ARPE-19 cell line (IC50 values 420 
were > 100 µM). The selectivity ratio for cisplatin (defined as the IC50 of ARPE-19 divided by 421 
the IC50 of cancer cell lines) was 1.23 for HCT-116 cells whereas for complex (3), the selectivity 422 
index was >2.64. Similar values for the selectivity index were obtained for other complexes 423 
tested suggesting that whilst potency is reduced compared to cisplatin, selectivity for cancer cells 424 
in vitro under identical experimental conditions is enhanced. 425 
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Conclusion 426 
In this work, we report the coordination chemistry of 2-substituted-1,8-naphthyridine 427 
ligands towards ruthenium, rhodium and iridium half-sandwich complexes. Complexes of PHNp 428 
and PyNp were isolated as neutral complexes whereas AnNp complexes were isolated as ionic 429 
salts with PF6 counter anion. The molecular structures of neutral complexes revealed that PHNp 430 
and PyNp ligands acted as monodentate ligand coordinating metal through napthyridine nitrogen 431 
(N1) and pyridine nitrogen N(1). Whereas the X-ray structures of cationic complexes with AnNp 432 
ligand showed that it behaved as neutral chelating ligand coordinating metal atom in a bidentate 433 
NN´ fashion through aniline nitrogen N(1) and napthyridine nitrogen (N2) forming a six-434 
membered chelated ring. Chemosensitivity activity of the complexes carried out against HCT-435 
116 and MIA-PaCa-2cancer cell lines showed that PHNp and its complexes are cytotoxic; 436 
however iridium-based AnNp complex possessed the highest activity among all other 437 
napthyridine complexes. The work presented here exhibits interesting coordination modes of the 438 
2-substituted-1,8-napthyridine ligands that have cytotoxic activity against cancer cells in vitro. 439 
Whilst the potency of these compounds is less than cisplatin, there is evidence to suggest that 440 
these complexes have greater selectivity for cancer as opposed to non-cancer cells in vitro than 441 
cisplatin and therefore representing promising compounds for further development and 442 
evaluation. 443 
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Scheme 1 Synthetic routes of ligands 500 
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 501 
Scheme 2 Synthesis of neutral and cationic napthyridine metal complexes (1-9) 502 
 503 
 504 
Figure 1 ORTEP plot of PHNp with 50% probability thermal ellipsoids. 505 
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 506 
Figure 2 ORTEP plot of complex (3) with 50% probability thermal ellipsoids. Hydrogen atoms 507 
(except on O1) are omitted for clarity. 508 
 509 
 510 
Figure 3 (a) ORTEP plot of complex (4) and (b) ORTEP plot of complex (5) with 50% 511 
probability thermal ellipsoids. Counter anions, hydrogen atoms (except on N1) are omitted for 512 
clarity. 513 
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 514 
Figure 4 ORTEP plot of complex (8) with 50% probability thermal ellipsoids. Solvent molecules 515 
and hydrogen atoms are omitted for clarity. 516 
 517 
Figure 5 ORTEP plot of complex (9) with 50% probability thermal ellipsoids. Solvent molecule 518 
and hydrogen atoms are omitted for clarity. 519 
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 520 
Figure 6 Packing diagram of complex (4) showing a dimeric unit formed via intermolecular van 521 
der Waal N-H·····Cl (2.647 Å) interaction between the terminal chloride and amino hydrogen. 522 
 523 
Figure 7 Packing diagram of complex (5) showing two different types of weak intermolecular 524 
van der Waal N-H·····Cl and C-H·····Cl interactions. 525 
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 526 
Figure 8 Crystal packing diagram of complex (8) showing a dimeric unit formed via 527 
intermolecular van der Waal C-H·····Cl  interactions. 528 
 529 
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Table1 Crystal data and structure refinement parameters of complexes 530 
Structures were refined on F02: wR2 = [Σ[w(F02 - Fc2)2] / Σw(F02)2]1/2, where w-1 = [Σ(F02)+(aP)2+bP] and P = [max(F02, 0)+2Fc2]/3 531 
Complexes PHNp [3]  [4] PF6. CH2Cl2 [5] PF6 [8] CHCl3 [9] CHCl3 
Empirical formula C14H10N2O C24H25Cl2N2OIr C25H27Cl3F6N5PRu C24H25ClF6N3PRh C24H25Cl5N3Rh C24H25Cl5N3Ir 
Formula weight 222.24 620.56 721.89 638.80 635.63 724.94 
Temperature (K) 295(5) 293.6(4) 294(2) 293.6(2) 293.46(16) 295.8(5) 
Wavelength (Å) 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073 
Crystal system monoclinic monoclinic triclinic triclinic monoclinic orthorhombic 
Space group P21/n P21/c P ͞1 P ͞1 P21/c Pbca 
a (Å)/α (°) 6.7873(9)/90 13.4948(7)/90 10.7040(6)/89.251 10.4457(6)/103.015(5) 14.6829(6)/90 14.5012(7)/90 
b (Å)/β (°) 7.4846(8)/91.156(11) 7.9005(4)/100.679(6) 12.2053(7)/72.359(5) 11.3360(6)/109.254(5) 13.1266(5)/104.747 14.1704(9)/90 
c (Å)/γ (°) 21.206(3)/90 21.1365(15)/90 13.0455(8)/64.432(5) 11.8077(6)/94.772(4) 14.4475(6)/90 26.0020(10)/90 
Volume (Å3) 1077.1(2)  2214.5(2) 1451.22(15)  1267.08(13) 2692.84(19) 5343.1(5) 
Z 4 4 2 2 4 11 
Density (calc) (Mg/m-3) 1.371 1.861 1.652 1.674 1.568 1.802 
Absorption coefficient (µ) 
(mm-1) 
0.089 0.832 0.931 0.906 1.148 5.516 
F(000) 464 1208 724 642 1280 2816 
Crystal size (mm3) 0.25 x 0.23 x 0.21 0.21 x 0.12 x 0.09 0.27 x 0.21 x 0.15 0.25 x 0.15 x 0.07 0.25 x 0.23 x 0.21 0.35 x 0.25 x 0.15 
Theta range for data collection 3.844 to 28.941° 3.240 to 29.075° 3.19 to 29.02° 3.332 to 29.115° 3.262 to 28.993° 3.5140 to 28.7290° 
Index ranges -9<=h<=5, -5<=k<=10, -
26<=l<=25 
-18<=h<=15, -5<=k<=10, 
-28<=l<=27 
-14<=h<=13, -
16<=k<=16, -17<=l<=16 
-14<=h<=14, -15<=k<=15, 
-40<=l<16 
-20<=h<=18, -
11<=k<=17, -19<=l<12 
-19<=h<=17, -
12<=k<=16, -
32<=l<18 
Reflections collected 3683 6905 10127 8777 11091 14307 
Independent reflections 2370 [R(int) = 0.0209] 4465 [R(int) = 0.0265] 6534 [R(int) = 0.0445] 5707 [R(int) = 0.0267] 6178 [R(int) =  0.0309] 5588 [R(int) =  
0.0317] 
Completeness to theta = 25.00° 96.2 %  89.5 %  99.5 %  99.5 %  99.3 %  78.7 %  
Absorption correction Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical 
from equivalents 
Max and min transmission 1.0000 and 0.67974 1.0000 and 0.36096 0.8730 and 0.7871 1.0000 and 0.69116 26.37 and 3.26 1.00000 and 
0.31067 
Refinement method Full-matrix least-squares 
on F2 
Full-matrix least-squares 
on F2 
Full-matrix least-squares 
on F2 
Full-matrix least-squares 
on F2 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Data/restraints/parameters 2370/0/154 4465/0/270 6534/5/377 5707/0/325 6178/0/298 6178/0/298 
Goodness-of-fit on F2 1.088 1.013 1.038 1.051 1.061 1.077 
Final R indices [I>2sigma(I)] R1 = 0.0566, wR2 = 
0.1361 
R1 = 0.0346, wR2 = 
0.0699 
R1 = 0.0552, wR2 = 
0.1360 
R1 = 0.0361, wR2 = 
0.0895 
R1 = 0.0505, wR2 = 
0.1047 
R1 = 0.0402, wR2 
= 0.0781 
R indices (all data) R1 = 0.0871, wR2 = 
0.1615 
R1 = 0.524, wR2 = 
0.0346 
R1 = 0.0691, wR2 = 
0.1469 
R1 = 0.0423, wR2 = 
0.0935 
R1 = 0.0664, wR2 = 
0.1127 
R1 = 0.0588, wR2 
= 0.0858 
Largest diff. peak and hole 
(e.Å-3) 
0.193 and -0.148 1.319 and -0.929 0.879 and -0.698 0.650 and -0.539 0.843 and -0.861 1.518 and -1.005 
CCDC No. 1568181 ---- 1568178 1568179 1568180 ---- 
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 Table 2 Selected bond lengths (Å) and bond angles (°) of complexes 532 
Complex 3 4 5 8 9 
M(1)-CNT 1.775 1.799 1.803 1.773 1.778 
M(1)-N(1) 2.154(4) 2.143(3) 2.138(2) 2.128(3) 2.117(5) 
M(1)-N(2) ---- 2.164(3) 2.179(3) 2.427(1)  
M(1)-Cl(1) 2.405(1) 2.4165(11) 2.4478(7) 2.405(1) 2.409(2) 
M(1)-Cl(2) 2.426(2) ---- ---- ---- 2.404(1) 
N(1)-M(1)-N(2) ---- 82.29(14) 80.12(8) ----  
N(1)-M(1)-Cl(1) 87.7(1) 82.67(10) 82.90(6) 87.27(8) 87.6(1) 
N(2)-M(1)-Cl(1) ---- 83.55(10) 91.00(6) ---- ---- 
N(1)-M(1)-Cl(2) 89.0(1) ---- ---- 89.76(8) 85.9(1) 
Cl(1)-M(1)-Cl(2) 85.13(5) ---- ---- 91.25(4) 89.46(5) 
CNT represents the centroid of the arene/Cp* ring and M = Ru, Rh and Ir. 533 
Table 3 IC50 values of napthyridine ligands and complexes (1-9) along with cisplatin against 534 
HCT-116 and MIA-PaCa-2 cancer cell line and non-cancer ARPE-19 cell line. Each value 535 
represents the mean ± standard deviation from three independent experiments. 536 
Compounds IC50 (µM) 
 HCT-116 MIA-PaCa-2 ARPE-19 
PHNp 39.90±1.64 62.48±6.28 >100 
AnNp >100 >100 >100 
PyNp >100 >100 >100 
Complex 1 82.09±3.54 >100 >100 
Complex 2 61.28±13.8 25.14±6.07 >100 
Complex 3 37.79±4.89 52.13±12.28 >100 
Complex 4 >100 >100 >100 
Complex 5 >100 >100 >100 
Complex 6 31.33±12.92 82.09±2.55 >100 
Complex 7 >100 >100 >100 
Complex 8 >100 >100 >100 
Complex 9 >100 >100 >100 
Cisplatin 2.78±1.40 3.15 ± 0.10 3.43±0.48 
IC50 = concentration of the drug required to inhibit the growth of 50% of the cancer cells (µM). 537 
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Highlights 
 2-substituted-napthyridine derivatives are synthesized by Friedländer 
condensation. 
 Interesting bonding modes of napthyridine ligands were observed. 
 Complexes were cytotoxic against cancer cell lines.  
